Antibody Drug Conjugates Market Size, Share & Trends Analysis Report By Application (Blood Cancer, Breast Cancer), By Technology (Type-cleavable, Non-cleavable), By Product, By Target, By Region, And Segment Forecasts, 2024

The global antibody drug conjugates market size is expected to reach USD 24.01 billion by 2030, registering a CAGR of 9.2% during the forecast period, according to a new report by Grand View Research, Inc. The presence of strong pipeline products and strategic initiatives undertaken by the key players are expected to drive the market growth during the forecast period.

Key players such as ADC Therapeutics, Seagen. Inc., Takeda Pharmaceutical Company Limited, F. Hoffmann-La Roche Ltd., AstraZeneca, Daiichi Sankyo, and others are collaborating to develop and commercialize products. For instance, in February 2022, Mersana Therapeutics, partnered with Janssen Pharmaceutical Companies, a subsidiary of Johnson & Johnson Inc., for the research and development of novel ADCs to treat various cancers. Under this agreement, Janssen will pay Mersana Therapeutics USD 40.0 million upfront and potentially more than USD 1.0 billion in milestone-based payments for the development of new ADCs.

Extensive research and rising funding for the development of novel antibody-drug conjugates by pharmaceutical companies is projected to drive market growth. For instance, in April 2021, Adcendo and Adcentrx, two new startups raised funding of around USD 112.0 million for the development of ADCs with their new approach to the treatment of cancer. Adcendo raised USD 51.0 million for the development of new ADCs that target endocytic receptors, which play the role of the drug delivery body. Adcentrx raised USD 50.0 million for its ADC research programs.

Additionally, in March 2022, ImmunoGen, Inc. announced the submission of biological license application (BLA) to the U.S. FDA for mirvetuximab soravtansine used as monotherapy in patients with ovarian cancer. It comprises alpha-binding antibody, cleavable linker, and the maytansinoid DM4 as payload to kill the targeted cancer cells.

Stringent reimbursement policies for ADCs may restrain the market growth due to the high cost associated with the treatment of ADCs as compared to the alternative conventional treatments such as monoclonal antibodies therapy & chemotherapy. This higher cost of treatment is expected to impede reimbursement coverage. For instance, in February 2020, National Centre for Pharmaco economics, Ireland, gave a negative review for Roche's Kadcyla (trastuzumab emtansine) for reimbursement consideration due to its low cost-effectiveness.

The rising geriatric population coupled with the increasing prevalence of the diseases such as multiple myeloma (MM) is expected to drive demand for ADCs, thereby driving the market growth during the forecast period. Multiple myeloma (MM) is a disease of the aging population, and nearly 30,000 new cases of MM were diagnosed in 2021. The median age of diagnosed patients with multiple myeloma is 70 years. Thus, the introduction of new ADCs for the treatment of multiple myeloma is expected to boost market growth. For instance, in August 2020, the FDA approved BLENREP by GlaxoSmithKline as a monotherapy to treat relapsed or refractory multiple myeloma. Blenrep was the first anti-BCMA therapy approved for the treatment of multiple myeloma.

Antibody Drug Conjugates Market Report Highlights:

Breast cancer dominated the market for the largest revenue share of 47.76% in 2023, owing to the high prevalence of breast cancer and the availability of multiple ADC products for treating the breast cancer
Cleavable linker segment accounted for largest revenue share of 72.43% in 2023 due to the rising adoption of cleavable linker technology in commercial ADC products and the advantages associated with the use of cleavable linkers over other linker technology
Based on linker Technology Type, others segment dominated the market due to presence of a large number of highly effective linkers in market such as SMCC, SPP, MCC, maleimide tetrapeptide, CL2A, and MC (Maleimidocaproyl) used to deliver payloads to their target sites.
North America dominated the market in terms of revenue share of 52.54% in 2023 due to the presence of key pharmaceutical companies such as Pfizer, Inc, Gilead Life Sciences, Inc., and Seagen, Inc. and their strategic initiatives for the development of new ADCs

Product Code: GVR-2-68038-741-4

Chapter 1. Methodology And Scope

1.1 Market Segmentation And Scope
- 1.1.1 Segment Definitions
  - 1.1.1.1 Application Segment
  - 1.1.1.2 Technology Segment
1.2 Regional Scope
1.3 Estimates And Forecast Timeline
1.4 Objectives
- 1.4.1 Objective - 1
- 1.4.2 Objective - 2
- 1.4.3 Objective - 3
1.5 Research Methodology
1.6 Information Procurement
- 1.6.1 Purchased Database
- 1.6.2 GVR' s Internal Database
- 1.6.3 Secondary Sources
- 1.6.4 Primary Research
1.7 Information Or Data Analysis
- 1.7.1 Data Analysis Models
1.8 Market Formulation & Validation
1.9 Model Details
- 1.9.1 Commodity Flow Analysis
1.10 List Of Secondary Sources
1.11 List Of Abbreviations

Chapter 2. Executive Summary

2.1. Market Snapshot
2.2. Technology And Application Snapshot
2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

3.1. Market Segmentation And Scope
3.2. Market Lineage Outlook
- 3.2.1. Parent Market Outlook
- 3.2.2. Related/Ancillary Market Outlook
3.3. Market Trends And Outlook
3.4. Market Dynamics
- 3.4.1. Presence Of Strong Product Pipeline
- 3.4.2. Growing Geriatric Population Base
- 3.4.3. Increasing Incidence And Prevalence Of Cancer
3.5. Market Restraint Analysis
- 3.5.1. High Manufacturing Cost And Downstream Processing Challenges For ADCs
- 3.5.2. Analytical Challenges For ADCs
- 3.5.3. Stringent Reimbursement Policies For ADCs
3.6. Business Environment Analysis
- 3.6.1. Swot Analysis; By Factor (Political & Legal, Economic And Technological)
- 3.6.2. Porter's Five Forces Analysis
- 3.6.3. Covid-19 Impact Analysis
3.7. Qualitative Analysis For ADC Development Platforms
- 3.7.1. Creative Biolabs
- 3.7.2. Mersana Therapeutics
- 3.7.3. Heidelberg Pharma
- 3.7.4. Synaffix BV
- 3.7.5. NBE Therapeutics
- 3.7.6. VERAXA
- 3.7.7. Tubulis Gmbh
- 3.7.8. Byondis Platform
- 3.7.9. Immunogen, Inc.
- 3.7.10. RemeGen
- 3.7.11. Wuxi Biologics
- 3.7.12. Merck & Co., Inc.
- 3.7.13. Ambrx

Chapter 4. Antibody Drug Conjugates Market: Segment Analysis By Application, 2018 - 2030 (USD Million)

4.1. Antibody Drug Conjugates Market: Application Movement Analysis
4.2. Blood Cancer
- 4.2.1. Blood Cancer Market, 2018 - 2030 (USD Million)
- 4.2.2. Leukemia
  - 4.2.2.1. Leukemia Market, 2018 - 2030 (USD Million)
- 4.2.3. Multiple Myeloma
  - 4.2.3.1. Multiple Myeloma Market, 2018 - 2030 (USD Million)
- 4.2.4. Lymphoma
  - 4.2.4.1. Lymphoma Market, 2018 - 2030 (USD Million)
4.3. Breast Cancer
4.4. Urothelial/Bladder Cancer
- 4.4.1. Urothelial/Bladder Cancer Market, 2018 - 2030 (USD Million)
4.5. Others
- 4.5.1. Others Market, 2018 - 2030 (USD Million)

Chapter 5. Antibody Drug Conjugates Market: Segment Analysis By Product, 2018 - 2030 (USD Million)

5.1. Antibody Drug Conjugates Market: Product Movement Analysis
5.2. Kadcyla
- 5.2.1. Kadcyla Market, 2018 - 2030 (USD Million)
5.3. Enhertu
- 5.3.1. Enhertu Market, 2018 - 2030 (USD Million)
5.4. Adcetris
- 5.4.1. Adcetris Market, 2018 - 2030 (USD Million)
5.5. Padcev
- 5.5.1. Padcev Market, 2018 - 2030 (USD Million)
5.6. Polivy
- 5.6.1. Polivy Market, 2018 - 2030 (USD Million)
5.7. Others
- 5.7.1. Others Market, 2018 - 2030 (USD Million)

Chapter 6. Antibody Drug Conjugates Market: Segment Analysis By Target, 2018 - 2030 (USD Million)

6.1. Antibody Drug Conjugates Market: Target Movement Analysis
6.2. HER2
- 6.2.1. HER2 Market, 2018 - 2030 (USD Million)
6.3. CD22
- 6.3.1. CD22 Market, 2018 - 2030 (USD Million)
6.4. CD30
- 6.4.1. CD30 Market, 2018 - 2030 (USD Million)
6.5. Others
- 6.5.1. Others market, 2018 - 2030 (USD Million)

Chapter 7. Antibody Drug Conjugates Market: Segment Analysis By Technology, 2018 - 2030 (USD Million)

7.1. Antibody Drug Conjugates Market: Technology Movement Analysis
7.2. By Type
- 7.2.1. Cleavable Linker
  - 7.2.1.1. Cleavable Linker Market, 2018 - 2030 (USD Million)
- 7.2.2. Non-Cleavable Linker
  - 7.2.2.1. Non-Cleavable Linker Market, 2018 - 2030 (USD Million)
- 7.2.3. Linkerless
  - 7.2.3.1. Linkerless Market, 2018 - 2030 (USD Million)
7.3. By Linker Technology
- 7.3.1. Vc (Valine-Citrulline)
  - 7.3.1.1. Vc Market, 2018 - 2030 (USD Million)
- 7.3.2. Sulfo-SPDB
  - 7.3.2.1. Sulfo-SPDB Market, 2018 - 2030 (USD Million)
- 7.3.3. VA (Valine Alanine)
  - 7.3.3.1. VA (Valine Alanine) Market, 2018 - 2030 (USD Million)
- 7.3.4. Hydrazone
  - 7.3.4.1. Hydrazone Market, 2018 - 2030 (USD Million)
- 7.3.5. Others
  - 7.3.5.1. Others Market, 2018 - 2030 (USD Million)
7.4. By Payload Technology
- 7.4.1. MMAE
  - 7.4.1.1. MMAE Market, 2018 - 2030 (USD Million)
- 7.4.2. MMAF
  - 7.4.2.1. MMAF Market, 2018 - 2030 (USD Million)
- 7.4.3. Dm4
  - 7.4.3.1. Dm4 Market, 2018 - 2030 (USD Million)
- 7.4.4. Camptothecin
  - 7.4.4.1. Camptothecin Market, 2018 - 2030 (USD Million)
- 7.4.5. Others
  - 7.4.5.1. Others Market, 2018 - 2030 (USD Million)

Chapter 8. Antibody Drug Conjugates Market: Regional Analysis, 2018 - 2030 (USD Million)

8.1. Antibody Drug Conjugates Market Share By Region, 2022 & 2030
8.2. North America
- 8.2.1. Swot Analysis
- 8.2.2. North America Antibody Drug Conjugates Market, 2018 - 2030 (USD Million)
- 8.2.3. U.S.
  - 8.2.3.1. Key Country Dynamics
  - 8.2.3.2. Target Disease Prevalence
  - 8.2.3.3. Competitive Scenario
  - 8.2.3.4. Regulatory Framework
  - 8.2.3.5. Reimbursement Scenario
  - 8.2.3.6. U.S. Antibody Drug Conjugates Market, 2018 - 2030 (USD Million)
- 8.2.4. Canada
  - 8.2.4.1. Key Country Dynamics
  - 8.2.4.2. Target Disease Prevalence
  - 8.2.4.3. Competitive Scenario
  - 8.2.4.4. Regulatory Framework
  - 8.2.4.5. Reimbursement Scenario
  - 8.2.4.6. Canada Antibody Drug Conjugates Market, 2018 - 2030 (USD Million)
8.3. Europe
- 8.3.1. Swot Analysis
- 8.3.2. Europe Antibody Drug Conjugates Market, 2018 - 2030 (USD Million)
- 8.3.3. Germany
  - 8.3.3.1. Key Country Dynamics
  - 8.3.3.2. Target Disease Prevalence
  - 8.3.3.3. Competitive Scenario
  - 8.3.3.4. Regulatory Framework
  - 8.3.3.5. Reimbursement Scenario
  - 8.3.3.6. Germany Antibody Drug Conjugates Market, 2018 - 2030 (USD Million)
- 8.3.4. UK
  - 8.3.4.1. Key Country Dynamics
  - 8.3.4.2. Target Disease Prevalence
  - 8.3.4.3. Competitive Scenario
  - 8.3.4.4. Regulatory Framework
  - 8.3.4.5. Reimbursement Scenario
  - 8.3.4.6. UK Antibody Drug Conjugates Market, 2018 - 2030 (USD Million)
- 8.3.5. France
  - 8.3.5.1. Key Country Dynamics
  - 8.3.5.2. Target Disease Prevalence
  - 8.3.5.3. Competitive Scenario
  - 8.3.5.4. Regulatory Framework
  - 8.3.5.5. Reimbursement Scenario
  - 8.3.5.6. France Antibody Drug Conjugates Market, 2018 - 2030 (USD Million)
- 8.3.6. Italy
  - 8.3.6.1. Key Country Dynamics
  - 8.3.6.2. Target Disease Prevalence
  - 8.3.6.3. Competitive Scenario
  - 8.3.6.4. Regulatory Framework
  - 8.3.6.5. Reimbursement Scenario
  - 8.3.6.6. Italy Antibody Drug Conjugates Market, 2018 - 2030 (USD Million)
- 8.3.7. Spain
  - 8.3.7.1. Key Country Dynamics
  - 8.3.7.2. Target Disease Prevalence
  - 8.3.7.3. Competitive Scenario
  - 8.3.7.4. Regulatory Framework
  - 8.3.7.5. Reimbursement Scenario
  - 8.3.7.6. Spain Antibody Drug Conjugates Market, 2018 - 2030 (USD Million)
- 8.3.8. Denmark
  - 8.3.8.1. Key Country Dynamics
  - 8.3.8.2. Target Disease Prevalence
  - 8.3.8.3. Competitive Scenario
  - 8.3.8.4. Regulatory Framework
  - 8.3.8.5. Reimbursement Scenario
  - 8.3.8.6. Denmark Antibody Drug Conjugates Market, 2018 - 2030 (USD Million)
- 8.3.9. Sweden
  - 8.3.9.1. Key Country Dynamics
  - 8.3.9.2. Target Disease Prevalence
  - 8.3.9.3. Competitive Scenario
  - 8.3.9.4. Regulatory Framework
  - 8.3.9.5. Reimbursement Scenario
  - 8.3.9.6. Sweden Antibody Drug Conjugates Market, 2018 - 2030 (USD Million)
- 8.3.10. Norway
  - 8.3.10.1. Key Country Dynamics
  - 8.3.10.2. Target Disease Prevalence
  - 8.3.10.3. Competitive Scenario
  - 8.3.10.4. Regulatory Framework
  - 8.3.10.5. Reimbursement Scenario
  - 8.3.10.6. Norway Antibody Drug Conjugates Market, 2018 - 2030 (USD Million)
8.4. Asia Pacific
- 8.4.1. Swot Analysis
- 8.4.2. Asia Pacific Antibody Drug Conjugates Market, 2018 - 2030 (USD Million)
- 8.4.3. Japan
  - 8.4.3.1. Key Country Dynamics
  - 8.4.3.2. Target Disease Prevalence
  - 8.4.3.3. Competitive Scenario
  - 8.4.3.4. Regulatory Framework
  - 8.4.3.5. Reimbursement Scenario
  - 8.4.3.6. Japan Antibody Drug Conjugates Market, 2018 - 2030 (USD Million)
- 8.4.4. China
  - 8.4.4.1. Key Country Dynamics
  - 8.4.4.2. Target Disease Prevalence
  - 8.4.4.3. Competitive Scenario
  - 8.4.4.4. Regulatory Framework
  - 8.4.4.5. Reimbursement Scenario
  - 8.4.4.6. China Antibody Drug Conjugates Market, 2018 - 2030 (USD Million)
- 8.4.5. India
  - 8.4.5.1. Key Country Dynamics
  - 8.4.5.2. Target Disease Prevalence
  - 8.4.5.3. Competitive Scenario
  - 8.4.5.4. Regulatory Framework
  - 8.4.5.5. Reimbursement Scenario
  - 8.4.5.6. India Antibody Drug Conjugates Market, 2018 - 2030 (USD Million)
- 8.4.6. South Korea
  - 8.4.6.1. Key Country Dynamics
  - 8.4.6.2. Target Disease Prevalence
  - 8.4.6.3. Competitive Scenario
  - 8.4.6.4. Regulatory Framework
  - 8.4.6.5. Reimbursement Scenario
  - 8.4.6.6. South Korea Antibody Drug Conjugates Market, 2018 - 2030 (USD Million)
- 8.4.7. Australia
  - 8.4.7.1. Key Country Dynamics
  - 8.4.7.2. Target Disease Prevalence
  - 8.4.7.3. Competitive Scenario
  - 8.4.7.4. Regulatory Framework
  - 8.4.7.5. Reimbursement Scenario
  - 8.4.7.6. Australia Antibody Drug Conjugates Market, 2018 - 2030 (USD Million)
- 8.4.8. Thailand
  - 8.4.8.1. Key Country Dynamics
  - 8.4.8.2. Target Disease Prevalence
  - 8.4.8.3. Competitive Scenario
  - 8.4.8.4. Regulatory Framework
  - 8.4.8.5. Reimbursement Scenario
  - 8.4.8.6. Thailand Antibody Drug Conjugates Market, 2018 - 2030 (USD Million)
8.5. Latin America
- 8.5.1. Swot Analysis
- 8.5.2. Latin America Antibody Drug Conjugates Market, 2018 - 2030 (USD Million)
- 8.5.3. Brazil
  - 8.5.3.1. Key Country Dynamics
  - 8.5.3.2. Target Disease Prevalence
  - 8.5.3.3. Competitive Scenario
  - 8.5.3.4. Regulatory Framework
  - 8.5.3.5. Reimbursement Scenario
  - 8.5.3.6. Brazil Antibody Drug Conjugates Market, 2018 - 2030 (USD Million)
- 8.5.4. Mexico
  - 8.5.4.1. Key Country Dynamics
  - 8.5.4.2. Target Disease Prevalence
  - 8.5.4.3. Competitive Scenario
  - 8.5.4.4. Regulatory Framework
  - 8.5.4.5. Reimbursement Scenario
  - 8.5.4.6. Mexico Antibody Drug Conjugates Market, 2018 - 2030 (USD Million)
- 8.5.5. Argentina
  - 8.5.5.1. Key Country Dynamics
  - 8.5.5.2. Target Disease Prevalence
  - 8.5.5.3. Competitive Scenario
  - 8.5.5.4. Regulatory Framework
  - 8.5.5.5. Reimbursement Scenario
  - 8.5.5.6. Argentina Antibody Drug Conjugates Market, 2018 - 2030 (USD Million)
8.8. Middle East and Africa (MEA)
- 8.8.1. Swot Analysis
- 8.8.2. MEA Antibody Drug Conjugates Market, 2018 - 2030 (USD Million)
- 8.8.3. South Africa
  - 8.8.3.1. Key Country Dynamics
  - 8.8.3.2. Target Disease Prevalence
  - 8.8.3.3. Competitive Scenario
  - 8.8.3.4. Regulatory Framework
  - 8.8.3.5. Reimbursement Scenario
  - 8.8.3.6. South Africa Antibody Drug Conjugates Market, 2018 - 2030 (USD Million)
- 8.8.4. Saudi Arabia
  - 8.8.4.1. Key Country Dynamics
  - 8.8.4.2. Target Disease Prevalence
  - 8.8.4.3. Competitive Scenario
  - 8.8.4.4. Regulatory Framework
  - 8.8.4.5. Reimbursement Scenario
  - 8.8.4.6. Saudi Arabia Antibody Drug Conjugates Market, 2018 - 2030 (USD Million)
- 8.8.5. UAE
  - 8.8.5.1. Key Country Dynamics
  - 8.8.5.2. Target Disease Prevalence
  - 8.8.5.3. Competitive Scenario
  - 8.8.5.4. Regulatory Framework
  - 8.8.5.5. Reimbursement Scenario
  - 8.8.5.6. UAE Antibody Drug Conjugates Market, 2018 - 2030 (USD Million)
- 8.8.6. Kuwait
  - 8.8.6.1. Key Country Dynamics
  - 8.8.6.2. Target Disease Prevalence
  - 8.8.6.3. Competitive Scenario
  - 8.8.6.4. Regulatory Framework
  - 8.8.6.5. Reimbursement Scenario
  - 8.8.6.6. Kuwait Antibody Drug Conjugates Market, 2018 - 2030 (USD Million)

Chapter 9. Competitive Landscape

9.1 Company Categorization
9.2 Strategy Mapping
- 9.2.1 New Product Launch
- 9.2.2 Partnerships
- 9.2.3 Acquisition
- 9.2.4 Collaboration
- 9.2.5 Funding
9.3 Key Company Market Share Analysis, 2023
9.4 Company Profiles
- 9.4.1 Takeda Pharmaceutical Company Limited
  - 9.4.1.1 Company Overview
  - 9.4.1.2 Financial Performance
  - 9.4.1.3 Product Benchmarking
  - 9.4.1.4 Strategic Initiatives
- 9.4.2 F.Hoffmann-La Roche Ltd.
  - 9.4.2.1 Company Overview
  - 9.4.2.2 Financial Performance
  - 9.4.2.3 Product Benchmarking
  - 9.4.2.4 Strategic Initiatives
- 9.4.3 Pfizer, Inc.
  - 9.4.3.1 Company Overview
  - 9.4.3.2 Financial Performance
  - 9.4.3.3 Product Benchmarking
  - 9.4.3.4 Strategic Initiatives
- 9.4.4 Astrazeneca
  - 9.4.4.1 Company Overview
  - 9.4.4.2 Product Benchmarking
  - 9.4.4.3 Strategic Initiatives
- 9.4.5 Gilead Sciences, Inc.
  - 9.4.5.1 Company Overview
  - 9.4.5.2 Financial Performance
  - 9.4.5.3 Product Benchmarking
  - 9.4.5.4 Strategic Initiatives
- 9.4.6 Astellas Pharma Inc.
  - 9.4.6.1 Company Overview
  - 9.4.6.2 Financial Performance
  - 9.4.6.3 Product Benchmarking
  - 9.4.6.4 Strategic Initiatives
- 9.4.7 Seagen, Inc.
  - 9.4.7.1 Company Overview
  - 9.4.7.2 Financial Performance
  - 9.4.7.3 Product Benchmarking
  - 9.4.7.4 Strategic Initiatives
- 9.4.8 Daiichi Sankyo Company, Limited
  - 9.4.8.1 Company Overview
  - 9.4.8.2 Financial Performance
  - 9.4.8.3 Product Benchmarking
  - 9.4.8.4 Strategic Initiatives
- 9.4.9 Glaxosmithkline Plc.
  - 9.4.9.1 Company Overview
  - 9.4.9.2 Financial Performance
  - 9.4.9.3 Product Benchmarking
  - 9.4.9.4 Strategic Initiatives
- 9.4.10 Adc Therapeutics Sa
  - 9.4.10.1 Company Overview
  - 9.4.10.2 Financial Performance
  - 9.4.10.3 Product Benchmarking
  - 9.4.10.4 Strategic Initiatives
- 9.4.11 Synaffix Bv
  - 9.4.11.1 Company Overview
  - 9.4.11.2 Financial Performance
  - 9.4.11.3 Product Benchmarking
  - 9.4.11.4 Strategic Initiatives

Chapter 10. Kol Recommendations/ Conclusion

Product Code: GVR-2-68038-741-4

List of Tables

TABLE 1 List of abbreviation
TABLE 2 List of secondary sources
TABLE 3 Global antibody-drug conjugates market estimates and forecasts, by region, 2018 - 2030 (USD Million)
TABLE 4 Global antibody-drug conjugates market estimates and forecasts, by application, 2018 - 2030 (USD Million)
TABLE 5 Global antibody-drug conjugates market estimates and forecasts, by product, 2018 - 2030 (USD Million)
TABLE 6 Global antibody-drug conjugates market estimates and forecasts, by target, 2018 - 2030 (USD Million)
TABLE 7 Global antibody-drug conjugates market estimates and forecasts, by technology type, 2018 - 2030 (USD Million)
TABLE 8 Global antibody-drug conjugates market estimates and forecasts, by linker technology, 2018 - 2030 (USD Million)
TABLE 9 Global antibody-drug conjugates market estimates and forecasts, by payload technology, 2018 - 2030 (USD Million)
TABLE 10 North America antibody-drug conjugates market estimates and forecasts, by country, 2018 - 2030 (USD Million)
TABLE 11 North America antibody-drug conjugates market estimates and forecasts, by application, 2018 - 2030 (USD Million)
TABLE 12 North America antibody-drug conjugates market estimates and forecasts, by product, 2018 - 2030 (USD Million)
TABLE 13 North America antibody-drug conjugates market estimates and forecasts, by target, 2018 - 2030 (USD Million)
TABLE 14 North America antibody-drug conjugates market estimates and forecasts, by technology type, 2018 - 2030 (USD Million)
TABLE 15 North America antibody-drug conjugates market estimates and forecasts, by linker technology, 2018 - 2030 (USD Million)
TABLE 16 North America antibody-drug conjugates market estimates and forecasts, by payload technology, 2018 - 2030 (USD Million)
TABLE 17 U.S. antibody-drug conjugates market estimates and forecasts, by application, 2018 - 2030 (USD Million)
TABLE 18 U.S. antibody-drug conjugates market estimates and forecasts, by product, 2018 - 2030 (USD Million)
TABLE 19 U.S. antibody-drug conjugates market estimates and forecasts, by target, 2018 - 2030 (USD Million)
TABLE 20 U.S. antibody-drug conjugates market estimates and forecasts, by technology type, 2018 - 2030 (USD Million)
TABLE 21 U.S. antibody-drug conjugates market estimates and forecasts, by linker technology, 2018 - 2030 (USD Million)
TABLE 22 U.S. antibody-drug conjugates market estimates and forecasts, by payload technology, 2018 - 2030 (USD Million)
TABLE 23 Canada antibody-drug conjugates market estimates and forecasts, by application, 2018 - 2030 (USD Million)
TABLE 24 Canada antibody-drug conjugates market estimates and forecasts, by product, 2018 - 2030 (USD Million)
TABLE 25 Canada antibody-drug conjugates market estimates and forecasts, by target, 2018 - 2030 (USD Million)
TABLE 26 Canada antibody-drug conjugates market estimates and forecasts, by technology type, 2018 - 2030 (USD Million)
TABLE 27 Canada antibody-drug conjugates market estimates and forecasts, by linker technology, 2018 - 2030 (USD Million)
TABLE 28 Canada antibody-drug conjugates market estimates and forecasts, by payload technology, 2018 - 2030 (USD Million)
TABLE 29 Europe antibody-drug conjugates market estimates and forecasts, by country, 2018 - 2030 (USD Million)
TABLE 30 Europe antibody-drug conjugates market estimates and forecasts, by country, 2018 - 2030 (USD Million)
TABLE 31 Europe antibody-drug conjugates market estimates and forecasts, by application, 2018 - 2030 (USD Million)
TABLE 32 Europe antibody-drug conjugates market estimates and forecasts, by product, 2018 - 2030 (USD Million)
TABLE 33 Europe antibody-drug conjugates market estimates and forecasts, by target, 2018 - 2030 (USD Million)
TABLE 34 Europe antibody-drug conjugates market estimates and forecasts, by technology type, 2018 - 2030 (USD Million)
TABLE 35 Europe antibody-drug conjugates market estimates and forecasts, by linker technology, 2018 - 2030 (USD Million)
TABLE 36 Europe antibody-drug conjugates market estimates and forecasts, by payload technology, 2018 - 2030 (USD Million)
TABLE 37 UK antibody-drug conjugates market estimates and forecasts, by application, 2018 - 2030 (USD Million)
TABLE 38 UK antibody-drug conjugates market estimates and forecasts, by product, 2018 - 2030 (USD Million)
TABLE 39 UK antibody-drug conjugates market estimates and forecasts, by target, 2018 - 2030 (USD Million)
TABLE 40 UK antibody-drug conjugates market estimates and forecasts, by technology type, 2018 - 2030 (USD Million)
TABLE 41 UK antibody-drug conjugates market estimates and forecasts, by linker technology, 2018 - 2030 (USD Million)
TABLE 42 UK antibody-drug conjugates market estimates and forecasts, by payload technology, 2018 - 2030 (USD Million)
TABLE 43 Germany antibody-drug conjugates market estimates and forecasts, by application, 2018 - 2030 (USD Million)
TABLE 44 Germany antibody-drug conjugates market estimates and forecasts, by product, 2018 - 2030 (USD Million)
TABLE 45 Germany antibody-drug conjugates market estimates and forecasts, by target, 2018 - 2030 (USD Million)
TABLE 46 Germany antibody-drug conjugates market estimates and forecasts, by technology type, 2018 - 2030 (USD Million)
TABLE 47 Germany antibody-drug conjugates market estimates and forecasts, by linker technology, 2018 - 2030 (USD Million)
TABLE 48 Germany antibody-drug conjugates market estimates and forecasts, by payload technology, 2018 - 2030 (USD Million)
TABLE 49 France antibody-drug conjugates market estimates and forecasts, by application, 2018 - 2030 (USD Million)
TABLE 50 France antibody-drug conjugates market estimates and forecasts, by product, 2018 - 2030 (USD Million)
TABLE 51 France antibody-drug conjugates market estimates and forecasts, by target, 2018 - 2030 (USD Million)
TABLE 52 France antibody-drug conjugates market estimates and forecasts, by technology type, 2018 - 2030 (USD Million)
TABLE 53 France antibody-drug conjugates market estimates and forecasts, by linker technology, 2018 - 2030 (USD Million)
TABLE 54 France antibody-drug conjugates market estimates and forecasts, by payload technology, 2018 - 2030 (USD Million)
TABLE 55 Italy antibody-drug conjugates market estimates and forecasts, by application, 2018 - 2030 (USD Million)
TABLE 56 Italy antibody-drug conjugates market estimates and forecasts, by product, 2018 - 2030 (USD Million)
TABLE 57 Italy antibody-drug conjugates market estimates and forecasts, by target, 2018 - 2030 (USD Million)
TABLE 58 Italy antibody-drug conjugates market estimates and forecasts, by technology type, 2018 - 2030 (USD Million)
TABLE 59 Italy antibody-drug conjugates market estimates and forecasts, by linker technology, 2018 - 2030 (USD Million)
TABLE 60 Italy antibody-drug conjugates market estimates and forecasts, by payload technology, 2018 - 2030 (USD Million)
TABLE 61 Spain antibody-drug conjugates market estimates and forecasts, by application, 2018 - 2030 (USD Million)
TABLE 62 Spain antibody-drug conjugates market estimates and forecasts, by product, 2018 - 2030 (USD Million)
TABLE 63 Spain antibody-drug conjugates market estimates and forecasts, by target, 2018 - 2030 (USD Million)
TABLE 64 Spain antibody-drug conjugates market estimates and forecasts, by technology type, 2018 - 2030 (USD Million)
TABLE 65 Spain antibody-drug conjugates market estimates and forecasts, by linker technology, 2018 - 2030 (USD Million)
TABLE 66 Spain antibody-drug conjugates market estimates and forecasts, by payload technology, 2018 - 2030 (USD Million)
TABLE 67 Denmark antibody-drug conjugates market estimates and forecasts, by application, 2018 - 2030 (USD Million)
TABLE 68 Denmark antibody-drug conjugates market estimates and forecasts, by product, 2018 - 2030 (USD Million)
TABLE 69 Denmark antibody-drug conjugates market estimates and forecasts, by target, 2018 - 2030 (USD Million)
TABLE 70 Denmark antibody-drug conjugates market estimates and forecasts, by technology type, 2018 - 2030 (USD Million)
TABLE 71 Denmark antibody-drug conjugates market estimates and forecasts, by linker technology, 2018 - 2030 (USD Million)
TABLE 72 Denmark antibody-drug conjugates market estimates and forecasts, by payload technology, 2018 - 2030 (USD Million)
TABLE 73 Sweden antibody-drug conjugates market estimates and forecasts, by application, 2018 - 2030 (USD Million)
TABLE 74 Sweden antibody-drug conjugates market estimates and forecasts, by product, 2018 - 2030 (USD Million)
TABLE 75 Sweden antibody-drug conjugates market estimates and forecasts, by application, 2018 - 2030 (USD Million)
TABLE 76 Sweden antibody-drug conjugates market estimates and forecasts, by technology type, 2018 - 2030 (USD Million)
TABLE 77 Sweden antibody-drug conjugates market estimates and forecasts, by linker technology, 2018 - 2030 (USD Million)
TABLE 78 Sweden antibody-drug conjugates market estimates and forecasts, by payload technology, 2018 - 2030 (USD Million)
TABLE 79 Norway antibody-drug conjugates market estimates and forecasts, by application, 2018 - 2030 (USD Million)
TABLE 80 Norway antibody-drug conjugates market estimates and forecasts, by product, 2018 - 2030 (USD Million)
TABLE 81 Norway antibody-drug conjugates market estimates and forecasts, by target, 2018 - 2030 (USD Million)
TABLE 82 Norway antibody-drug conjugates market estimates and forecasts, by technology type, 2018 - 2030 (USD Million)
TABLE 83 Norway antibody-drug conjugates market estimates and forecasts, by linker technology, 2018 - 2030 (USD Million)
TABLE 84 Norway antibody-drug conjugates market estimates and forecasts, by payload technology, 2018 - 2030 (USD Million)
TABLE 85 Asia Pacific antibody-drug conjugates market estimates and forecasts, by application, 2018 - 2030 (USD Million)
TABLE 86 Asia Pacific antibody-drug conjugates market estimates and forecasts, by product, 2018 - 2030 (USD Million)
TABLE 87 Asia Pacific antibody-drug conjugates market estimates and forecasts, by target, 2018 - 2030 (USD Million)
TABLE 88 Asia Pacific antibody-drug conjugates market estimates and forecasts, by technology type, 2018 - 2030 (USD Million)
TABLE 89 Asia Pacific antibody-drug conjugates market estimates and forecasts, by linker technology, 2018 - 2030 (USD Million)
TABLE 90 Asia Pacific antibody-drug conjugates market estimates and forecasts, by payload technology, 2018 - 2030 (USD Million)
TABLE 91 Japan antibody-drug conjugates market estimates and forecasts, by application, 2018 - 2030 (USD Million)
TABLE 92 Japan antibody-drug conjugates market estimates and forecasts, by product, 2018 - 2030 (USD Million)
TABLE 93 Japan antibody-drug conjugates market estimates and forecasts, by target, 2018 - 2030 (USD Million)
TABLE 94 Japan antibody-drug conjugates market estimates and forecasts, by technology type, 2018 - 2030 (USD Million)
TABLE 95 Japan antibody-drug conjugates market estimates and forecasts, by linker technology, 2018 - 2030 (USD Million)
TABLE 96 Japan antibody-drug conjugates market estimates and forecasts, by payload technology, 2018 - 2030 (USD Million)
TABLE 97 China antibody-drug conjugates market estimates and forecasts, by application, 2018 - 2030 (USD Million)
TABLE 98 China antibody-drug conjugates market estimates and forecasts, by product, 2018 - 2030 (USD Million)
TABLE 99 China antibody-drug conjugates market estimates and forecasts, by target, 2018 - 2030 (USD Million)
TABLE 100 China antibody-drug conjugates market estimates and forecasts, by technology type, 2018 - 2030 (USD Million)
TABLE 101 China antibody-drug conjugates market estimates and forecasts, by linker technology, 2018 - 2030 (USD Million)
TABLE 102 China antibody-drug conjugates market estimates and forecasts, by payload technology, 2018 - 2030 (USD Million)
TABLE 103 India antibody-drug conjugates market estimates and forecasts, by application, 2018 - 2030 (USD Million)
TABLE 104 India antibody-drug conjugates market estimates and forecasts, by product, 2018 - 2030 (USD Million)
TABLE 105 India antibody-drug conjugates market estimates and forecasts, by target, 2018 - 2030 (USD Million)
TABLE 106 India antibody-drug conjugates market estimates and forecasts, by technology type, 2018 - 2030 (USD Million)
TABLE 107 India antibody-drug conjugates market estimates and forecasts, by linker technology, 2018 - 2030 (USD Million)
TABLE 108 India antibody-drug conjugates market estimates and forecasts, by payload technology, 2018 - 2030 (USD Million)
TABLE 109 Australia antibody-drug conjugates market estimates and forecasts, by application, 2018 - 2030 (USD Million)
TABLE 110 Australia antibody-drug conjugates market estimates and forecasts, by product, 2018 - 2030 (USD Million)
TABLE 111 Australia antibody-drug conjugates market estimates and forecasts, by target, 2018 - 2030 (USD Million)
TABLE 112 Australia antibody-drug conjugates market estimates and forecasts, by technology type, 2018 - 2030 (USD Million)
TABLE 113 Australia antibody-drug conjugates market estimates and forecasts, by linker technology, 2018 - 2030 (USD Million)
TABLE 114 Australia antibody-drug conjugates market estimates and forecasts, by payload technology, 2018 - 2030 (USD Million)
TABLE 115 South Korea antibody-drug conjugates market estimates and forecasts, by application, 2018 - 2030 (USD Million)
TABLE 116 South Korea antibody-drug conjugates market estimates and forecasts, by product, 2018 - 2030 (USD Million)
TABLE 117 South Korea antibody-drug conjugates market estimates and forecasts, by target, 2018 - 2030 (USD Million)
TABLE 118 South Korea antibody-drug conjugates market estimates and forecasts, by technology type, 2018 - 2030 (USD Million)
TABLE 119 South Korea antibody-drug conjugates market estimates and forecasts, by linker technology, 2018 - 2030 (USD Million)
TABLE 120 South Korea antibody-drug conjugates market estimates and forecasts, by payload technology, 2018 - 2030 (USD Million)
TABLE 121 Thailand antibody-drug conjugates market estimates and forecasts, by application, 2018 - 2030 (USD Million)
TABLE 122 Thailand antibody-drug conjugates market estimates and forecasts, by product, 2018 - 2030 (USD Million)
TABLE 123 Thailand antibody-drug conjugates market estimates and forecasts, by target, 2018 - 2030 (USD Million)
TABLE 124 Thailand antibody-drug conjugates market estimates and forecasts, by technology type, 2018 - 2030 (USD Million)
TABLE 125 Thailand antibody-drug conjugates market estimates and forecasts, by linker technology, 2018 - 2030 (USD Million)
TABLE 126 Thailand antibody-drug conjugates market estimates and forecasts, by payload technology, 2018 - 2030 (USD Million)
TABLE 127 Latin America antibody-drug conjugates market estimates and forecasts, by application, 2018 - 2030 (USD Million)
TABLE 128 Latin America antibody-drug conjugates market estimates and forecasts, by product, 2018 - 2030 (USD Million)
TABLE 129 Latin America antibody-drug conjugates market estimates and forecasts, by target, 2018 - 2030 (USD Million)
TABLE 130 Latin America antibody-drug conjugates market estimates and forecasts, by technology type, 2018 - 2030 (USD Million)
TABLE 131 Latin America antibody-drug conjugates market estimates and forecasts, by linker technology, 2018 - 2030 (USD Million)
TABLE 132 Latin America antibody-drug conjugates market estimates and forecasts, by payload technology, 2018 - 2030 (USD Million)
TABLE 133 Brazil antibody-drug conjugates market estimates and forecasts, by application, 2018 - 2030 (USD Million)
TABLE 134 Brazil antibody-drug conjugates market estimates and forecasts, by product, 2018 - 2030 (USD Million)
TABLE 135 Brazil antibody-drug conjugates market estimates and forecasts, by target, 2018 - 2030 (USD Million)
TABLE 136 Brazil antibody-drug conjugates market estimates and forecasts, by technology type, 2018 - 2030 (USD Million)
TABLE 137 Brazil antibody-drug conjugates market estimates and forecasts, by linker technology, 2018 - 2030 (USD Million)
TABLE 138 Brazil antibody-drug conjugates market estimates and forecasts, by payload technology, 2018 - 2030 (USD Million)
TABLE 139 Mexico antibody-drug conjugates market estimates and forecasts, by application, 2018 - 2030 (USD Million)
TABLE 140 Mexico antibody-drug conjugates market estimates and forecasts, by product, 2018 - 2030 (USD Million)
TABLE 141 Mexico antibody-drug conjugates market estimates and forecasts, by target, 2018 - 2030 (USD Million)
TABLE 142 Mexico antibody-drug conjugates market estimates and forecasts, by technology type, 2018 - 2030 (USD Million)
TABLE 143 Mexico antibody-drug conjugates market estimates and forecasts, by linker technology, 2018 - 2030 (USD Million)
TABLE 144 Mexico antibody-drug conjugates market estimates and forecasts, by payload technology, 2018 - 2030 (USD Million)
TABLE 145 Argentina antibody-drug conjugates market estimates and forecasts, by application, 2018 - 2030 (USD Million)
TABLE 146 Argentina antibody-drug conjugates market estimates and forecasts, by product, 2018 - 2030 (USD Million)
TABLE 147 Argentina antibody-drug conjugates market estimates and forecasts, by target, 2018 - 2030 (USD Million)
TABLE 148 Argentina antibody-drug conjugates market estimates and forecasts, by technology type, 2018 - 2030 (USD Million)
TABLE 149 Argentina antibody-drug conjugates market estimates and forecasts, by linker technology, 2018 - 2030 (USD Million)
TABLE 150 Argentina antibody-drug conjugates market estimates and forecasts, by payload technology, 2018 - 2030 (USD Million)
TABLE 151 MEA antibody-drug conjugates market estimates and forecasts, by application, 2018 - 2030 (USD Million)
TABLE 152 MEA antibody-drug conjugates market estimates and forecasts, by product, 2018 - 2030 (USD Million)
TABLE 153 MEA antibody-drug conjugates market estimates and forecasts, by target, 2018 - 2030 (USD Million)
TABLE 154 MEA antibody-drug conjugates market estimates and forecasts, by technology type, 2018 - 2030 (USD Million)
TABLE 155 MEA antibody-drug conjugates market estimates and forecasts, by linker technology, 2018 - 2030 (USD Million)
TABLE 156 MEA antibody-drug conjugates market estimates and forecasts, by payload technology, 2018 - 2030 (USD Million)
TABLE 157 South Africa antibody-drug conjugates market estimates and forecasts, by application, 2018 - 2030 (USD Million)
TABLE 158 South Africa antibody-drug conjugates market estimates and forecasts, by product, 2018 - 2030 (USD Million)
TABLE 159 South Africa antibody-drug conjugates market estimates and forecasts, by target, 2018 - 2030 (USD Million)
TABLE 160 South Africa antibody-drug conjugates market estimates and forecasts, by technology type, 2018 - 2030 (USD Million)
TABLE 161 South Africa antibody-drug conjugates market estimates and forecasts, by linker technology, 2018 - 2030 (USD Million)
TABLE 162 South Africa antibody-drug conjugates market estimates and forecasts, by payload technology, 2018 - 2030 (USD Million)
TABLE 163 Saudi Arabia antibody-drug conjugates market estimates and forecasts, by application, 2018 - 2030 (USD Million)
TABLE 164 Saudi Arabia antibody-drug conjugates market estimates and forecasts, by product, 2018 - 2030 (USD Million)
TABLE 165 Saudi Arabia antibody-drug conjugates market estimates and forecasts, by target, 2018 - 2030 (USD Million)
TABLE 166 Saudi Arabia antibody-drug conjugates market estimates and forecasts, by technology type, 2018 - 2030 (USD Million)
TABLE 167 Saudi Arabia antibody-drug conjugates market estimates and forecasts, by linker technology, 2018 - 2030 (USD Million)
TABLE 168 Saudi Arabia antibody-drug conjugates market estimates and forecasts, by payload technology, 2018 - 2030 (USD Million)
TABLE 169 UAE antibody-drug conjugates market estimates and forecasts, by application, 2018 - 2030 (USD Million)
TABLE 170 UAE antibody-drug conjugates market estimates and forecasts, by product, 2018 - 2030 (USD Million)
TABLE 171 UAE antibody-drug conjugates market estimates and forecasts, by target, 2018 - 2030 (USD Million)
TABLE 172 UAE antibody-drug conjugates market estimates and forecasts, by technology type, 2018 - 2030 (USD Million)
TABLE 173 UAE antibody-drug conjugates market estimates and forecasts, by linker technology, 2018 - 2030 (USD Million)
TABLE 174 UAE antibody-drug conjugates market estimates and forecasts, by payload technology, 2018 - 2030 (USD Million)
TABLE 175 Kuwait antibody-drug conjugates market estimates and forecasts, by application, 2018 - 2030 (USD Million)
TABLE 176 Kuwait antibody-drug conjugates market estimates and forecasts, by product, 2018 - 2030 (USD Million)
TABLE 177 Kuwait antibody-drug conjugates market estimates and forecasts, by target, 2018 - 2030 (USD Million)
TABLE 178 Kuwait antibody-drug conjugates market estimates and forecasts, by technology type, 2018 - 2030 (USD Million)
TABLE 179 Kuwait antibody-drug conjugates market estimates and forecasts, by linker technology, 2018 - 2030 (USD Million)
TABLE 180 Kuwait antibody-drug conjugates market estimates and forecasts, by payload technology, 2018 - 2030 (USD Million)
TABLE 181 List of key distributors
TABLE 182 List of key emerging companies/technology disruptors/innovators

List of Figures

FIG. 1 Antibody-drug conjugates market segmentation
FIG. 2 Market research process
FIG. 3 Data triangulation techniques
FIG. 4 Primary research pattern
FIG. 5 Market research approaches
FIG. 6 Value-chain-based sizing & forecasting
FIG. 7 QFD modeling for market share assessment
FIG. 8 Market formulation & validation
FIG. 9 Antibody-drug conjugates market snapshot
FIG. 10 Antibody-drug conjugates market driver impact
FIG. 11 Global population by age group, 2016, 2022, & 2027
FIG. 12 Global cancer cases projection,2020 - 2030 (Number of new registered cases)
FIG. 13 Antibody-drug conjugates market restraint impact
FIG. 14 Penetration and growth prospect mapping
FIG. 15 SWOT analysis, by factor (political & legal economic and technological)
FIG. 16 Porter's five forces analysis
FIG. 17 Antibody-drug conjugates market: Application outlook and key takeaways
FIG. 18 Antibody-drug conjugates market: Application movement analysis
FIG. 19 Blood cancer market estimates and forecasts, 2018 - 2030
FIG. 20 Leukemia market estimates and forecasts, 2018 - 2030
FIG. 21 Multiple Myeloma market estimates and forecasts, 2018 - 2030
FIG. 22 Lymphoma market estimates and forecasts, 2018 - 2030
FIG. 23 Breast cancer market estimates and forecasts, 2018 - 2030
FIG. 24 Urothelial cancer market estimates and forecasts, 2018 - 2030
FIG. 25 Others market estimates and forecasts, 2018 - 2030
FIG. 26 Antibody-drug conjugates market: Product outlook and key takeaways
FIG. 27 Antibody-drug conjugates market: Product movement analysis
FIG. 28 Kadcyla market estimates and forecasts, 2018 - 2030
FIG. 29 Enhertu market estimates and forecasts, 2018 - 2030
FIG. 30 Adcetris market estimates and forecasts, 2018 - 2030
FIG. 31 Padcev market estimates and forecasts, 2018 - 2030
FIG. 32 Trodelvy market estimates and forecasts, 2018 - 2030
FIG. 33 Polivy market estimates and forecasts, 2018 - 2030
FIG. 34 Others market estimates and forecasts, 2018 - 2030
FIG. 35 Antibody-drug conjugates market: Target outlook and key takeaways
FIG. 36 Antibody-drug conjugates market: Target movement analysis
FIG. 37 HER2 market estimates and forecasts, 2018 - 2030
FIG. 38 CD22 market estimates and forecasts, 2018 - 2030
FIG. 39 CD30 market estimates and forecasts, 2018 - 2030
FIG. 40 Others market estimates and forecasts, 2018 - 2030
FIG. 41 Antibody-drug conjugates market: Technology outlook and key takeaways
FIG. 42 Antibody-drug conjugates market: Technology movement analysis
FIG. 43 Cleavable linker market estimates and forecasts, 2018 - 2030
FIG. 44 Non-cleavable linker market estimates and forecasts, 2018 - 2030
FIG. 45 Linkerless market estimates and forecasts, 2018 - 2030
FIG. 46 VC (valine-citrulline) market estimates and forecasts, 2018 - 2030
FIG. 47 Sulfo-SPDB market estimates and forecasts, 2018 - 2030
FIG. 48 VA (valine alanine) market estimates and forecasts, 2018 - 2030
FIG. 49 Hydrazone market estimates and forecasts, 2018 - 2030
FIG. 50 Others market estimates and forecasts, 2018 - 2030
FIG. 51 MMAE market estimates and forecasts, 2018 - 2030
FIG. 52 MMAF market estimates and forecasts, 2018 - 2030
FIG. 53 DM4 market estimates and forecasts, 2018 - 2030
FIG. 54 Camptothecin market estimates and forecasts, 2018 - 2030
FIG. 55 Others market estimates and forecasts, 2018 - 2030
FIG. 56 Antibody-drug conjugates market: Regional outlook and key takeaways
FIG. 57 Antibody-drug conjugates market: Regional movement analysis
FIG. 58 North America SWOT analysis
FIG. 59 North America market estimates and forecast, 2018 - 2030 (USD Million)
FIG. 60 U.S. key country dynamics
FIG. 61 U.S. market estimates and forecast, 2018 - 2030 (USD Million)
FIG. 62 Canada key country dynamics
FIG. 63 Canada market estimates and forecast, 2018 - 2030 (USD Million)
FIG. 64 Europe SWOT analysis
FIG. 65 Europe market estimates and forecast, 2018 - 2030 (USD Million)
FIG. 66 UK key country dynamics
FIG. 67 UK market estimates and forecast, 2018 - 2030 (USD Million)
FIG. 68 Germany key country dynamics
FIG. 69 Germany market estimates and forecast, 2018 - 2030 (USD Million)
FIG. 70 Italy key country dynamics
FIG. 71 Italy market estimates and forecast, 2018 - 2030 (USD Million)
FIG. 72 Spain key country dynamics
FIG. 73 Spain market estimates and forecast, 2018 - 2030 (USD Million)
FIG. 74 Denmark key country dynamics
FIG. 75 Denmark market estimates and forecast, 2018 - 2030 (USD Million)
FIG. 76 Sweden key country dynamics
FIG. 77 Sweden market estimates and forecast, 2018 - 2030 (USD Million)
FIG. 78 Norway key country dynamics
FIG. 79 Norway market estimates and forecast, 2018 - 2030 (USD Million)
FIG. 80 France key country dynamics
FIG. 81 France market estimates and forecast, 2018 - 2030 (USD Million)
FIG. 82 Asia Pacific SWOT analysis
FIG. 83 Asia Pacific market estimates and forecast, 2018 - 2030 (USD Million)
FIG. 84 Japan key country dynamics
FIG. 85 Japan market estimates and forecast, 2018 - 2030 (USD Million)
FIG. 86 China key country dynamics
FIG. 87 China market estimates and forecast, 2018 - 2030 (USD Million)
FIG. 88 India key country dynamics
FIG. 89 India market estimates and forecast, 2018 - 2030 (USD Million)
FIG. 90 Australia key country dynamics
FIG. 91 Australia market estimates and forecast, 2018 - 2030 (USD Million)
FIG. 92 South Korea key country dynamics
FIG. 93 South Korea market estimates and forecast, 2018 - 2030 (USD Million)
FIG. 94 Thailand key country dynamics
FIG. 95 Thailand market estimates and forecast, 2018 - 2030 (USD Million)
FIG. 96 Latin America SWOT analysis
FIG. 97 Latin America market estimates and forecast, 2018 - 2030 (USD Million)
FIG. 98 Brazil key country dynamics
FIG. 99 Brazil market estimates and forecast, 2018 - 2030 (USD Million)
FIG. 100 Mexico key country dynamics
FIG. 101 Mexico market estimates and forecast, 2018 - 2030 (USD Million)
FIG. 102 Argentina key country dynamics
FIG. 103 Argentina market estimates and forecast, 2018 - 2030 (USD Million)
FIG. 104 Middle East & Africa SWOT analysis
FIG. 105 Middle East and Africa market estimates and forecast, 2018 - 2030 (USD Million)
FIG. 106 South Africa key country dynamics
FIG. 107 South Africa market estimates and forecast, 2018 - 2030 (USD Million)
FIG. 108 Saudi Arabia key country dynamics
FIG. 109 Saudi Arabia market estimates and forecast, 2018 - 2030 (USD Million)
FIG. 110 UAE key country dynamics
FIG. 111 UAE market estimates and forecast, 2018 - 2030 (USD Million)
FIG. 112 Kuwait key country dynamics
FIG. 113 Kuwait market estimates and forecast, 2018 - 2030 (USD Million)
FIG. 114 Company market share analysis
FIG. 115 Company market position analysis (Revenue US$ mn)
FIG. 116 Company market position analysis (Profit Margin)
FIG. 117 Competitive dashboard analysis
FIG. 118 Regional Network Map

Antibody Drug Conjugates Market Size, Share & Trends Analysis Report By Application (Blood Cancer, Breast Cancer), By Technology (Type-cleavable, Non-cleavable), By Product, By Target, By Region, And Segment Forecasts, 2024 - 2030

Description

Table of Contents

List of Tables

Antibody Drug Conjugates Market Growth & Trends:

Antibody Drug Conjugates Market Report Highlights:

Table of Contents

Chapter 1. Methodology And Scope

Chapter 2. Executive Summary

Chapter 3. Market Variables, Trends, & Scope

Chapter 4. Antibody Drug Conjugates Market: Segment Analysis By Application, 2018 - 2030 (USD Million)

Chapter 5. Antibody Drug Conjugates Market: Segment Analysis By Product, 2018 - 2030 (USD Million)

Chapter 6. Antibody Drug Conjugates Market: Segment Analysis By Target, 2018 - 2030 (USD Million)

Chapter 7. Antibody Drug Conjugates Market: Segment Analysis By Technology, 2018 - 2030 (USD Million)

Chapter 8. Antibody Drug Conjugates Market: Regional Analysis, 2018 - 2030 (USD Million)

Chapter 9. Competitive Landscape

Chapter 10. Kol Recommendations/ Conclusion

List of Tables

List of Figures